Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer.
Philip G TurnerSuneil JainAidan ColeArthur GreyDarren MitchellKevin M PriseAlan R HounsellConor K McGarrySandra BiggartJoe M O'SullivanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
This is the first trial of combination ADT, radium-223, and EBRT to pelvis, post docetaxel. The combination was safe, with an efficacy signal. Multicenter randomized controlled trials (RCT) are warranted.
Keyphrases
- prostate cancer
- locally advanced
- rectal cancer
- randomized controlled trial
- squamous cell carcinoma
- early stage
- study protocol
- small cell lung cancer
- clinical trial
- radical prostatectomy
- radiation therapy
- stem cells
- phase ii
- cross sectional
- systematic review
- mesenchymal stem cells
- double blind
- open label
- meta analyses